Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 204.

Richtig, G; Ramelyte, E; Koch, L; Greinix, H; Ferrone, S; Dummer, R; Richtig, E (2019). Unmasking of a primary desmoplastic melanoma tumour in the course of treatment of a metastatic disease with anti-PD-1 monoclonal antibody. Journal of the European Academy of Dermatology and Venerology:Epub ahead of print.

Li, Yan; Tinoco, Roberto; Elmén, Lisa; et al; Levesque, Mitchell P; Dummer, R (2019). Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5 mice. Nature Communications, 10(1):1492.

Koelblinger, P; Emberger, M; Drach, M; Cheng, PF; Lang, R; Levesque, MP; Bauer, JW; Dummer, R (2019). Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. Journal of the European Academy of Dermatology and Venerology, 33(4):667-675.

Graf, N P; Koelblinger, P; Galliker, N; Conrad, S; Barysch, M; Mangana, J; Dummer, R; Cheng, P F; Goldinger, S M (2019). The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma. Journal of the European Academy of Dermatology and Venerology, 33(4):686-692.

Stockfleth, E; Hofbauer, G F L; Reinhold, U; Popp, G; Hengge, U R; Szeimies, R M; Brüning, H; Anliker, M; Hunger, T; Dummer, R; Ulrich, C; Kenzelmann, R; Surber, C; French, L E (2019). Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial. British Journal of Dermatology, 180(2):297-305.

Johnson, Douglas B.; Dummer, R; Flaherty, Keith T; Smalley, Keiran S (2019). Targeted Therapies for BRAF-mutant metastatic Melanoma. In: Johnson, Douglas B. Live, Cutaneous Melanoma. Switzerland, 1-19.

Kandolf Sekulovic, L; et al; Dummer, R (2018). Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. European Journal of Cancer, 104:201-209.

Roider, E; Signer, C; Fehrenbacher, B; Metzler, G; Schaller, M; Kamarachev, J; Kerl, K; Balabanov, S; Jochum, W; Hoetzenecker, W; Cozzio, A; French, L; Dummer, R; Guenova, E (2018). Individualized treatment approaches for Langerhans cell histiocytosis. British Journal of Dermatology, 178(6):1423-1424.

Luder, C M; Nordmann, T M; Ramelyte, E; Mühleisen, B; Kerl, K; Guenova, E; Dummer, R (2018). Histiocytosis - cutaneous manifestations of hematopoietic neoplasm and non-neoplastic histiocytic proliferations. Journal of the European Academy of Dermatology and Venerology, 32(6):926-934.

Lear, J T; Migden, M R; Lewis, K D; Chang, A L S; Guminski, A; Gutzmer, R; Dirix, L; Combemale, P; Stratigos, A; Plummer, R; Castro, H; Yi, T; Mone, M; Zhou, J; Trefzer, U; Kaatz, M; Loquai, C; Kudchadkar, R; Sellami, D; Dummer, R (2018). Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. Journal of the European Academy of Dermatology and Venerology, 32(3):372-381.

Basset-Séguin, N; Hauschild, A; Kunstfeld, R; Grob, J; Dréno, B; Mortier, L; Ascierto, P A; Licitra, L; Dutriaux, C; Thomas, L; Meyer, N; Guillot, B; Dummer, R; Arenberger, P; Fife, K; Raimundo, A; Dika, E; Dimier, N; Fittipaldo, A; Xynos, I; Hansson, J (2017). Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. European Journal of Cancer, 86:334-348.

Chapman, P B; Robert, C; Larkin, J; Haanen, J B; Ribas, A; Hogg, D; Hamid, O; Ascierto, P A; Testori, A; Lorigan, P C; Dummer, R; Sosman, J A; Flaherty, K T; Chang, I; Coleman, S; Caro, I; Hauschild, A; McArthur, G A (2017). Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Annals of Oncology, 28(10):2581-2587.

Brüggemann, C; Kirchberger, M C; Goldinger, S M; Weide, B; Konrad, A; Erdmann, M; Schadendorf, D; Croner, R S; Krähenbühl, L; Kähler, K C; Hafner, C; Leisgang, W; Kiesewetter, F; Dummer, R; Schuler, G; Stürzl, M; Heinzerling, L (2017). Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Journal of Cancer Research and Clinical Oncology, 143(10):1977-1984.

Schaefer, S M; Segalada, C; Cheng, P F; Bonalli, M; Parfejevs, V; Levesque, M P; Dummer, R; Nicolis, S K; Sommer, L (2017). Sox2 is dispensable for primary melanoma and metastasis formation. Oncogene, 36(31):4516-4524.

Guo, J; Carvajal, R D; Dummer, R; et al (2017). Efficacy and Safety of Nilotinib in Patients With KIT-Mutated Metastatic or Inoperable Melanoma: Final Results From the Global, Single-Arm, Phase II TEAM Trial. Annals of Oncology, 28(6):1380-1387.

Nonomura, Y; Otsuka, A; Ohtsuka, M; Yamamoto, T; Dummer, R; Kabashima, K (2017). ADAMTSL5 is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab. Journal of the European Academy of Dermatology and Venerology, 31(2):e100-e101.

Crisan, D; Scharffetter-Kochanek, K; Dummer, R; Treiber, N; Sindrilaru, A; Kastler, S; Schneider, L A (2017). Beware when the hair turns dark again: clinical presentation and management of melanoma in situ in a giant congenital naevus on the scalp. Journal of the European Academy of Dermatology and Venerology, 31(5):e226-e228.

Amann, V C; Ramelyte, E; Thurneysen, S; Pitocco, R; Bentele-Jaberg, N; Goldinger, S M; Dummer, R; Mangana, J (2017). Developments in targeted therapy in melanoma. European Journal of Surgical Oncology, 43(3):581-593.

Kandolf Sekulovic, L; Peris, K; Hauschild, A; Stratigos, A; Grob, J-J; Nathan, P; Dummer, R; Forsea, A-M; Hoeller, C; Gogas, H; Demidov, L; Lebbe, C; Blank, C; Olah, J; Bastholt, L; Herceg, D; Neyns, B; Vieira, R; Hansson, J; Rutkowski, P; Krajsova, I; Bylaite-Bucinskiene, M; Zalaudek, I; Maric-Brozic, J; Babovic, N; Banjin, M; Putnik, K; Weinlich, G; Todorovic, V; Kirov, K; et al (2017). More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. European Journal of Cancer, 75:313-322.

Amann, V C; Hoffmann, D; Mangana, J; Dummer, R; Goldinger, S M (2017). Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma. Journal of the European Academy of Dermatology and Venerology, 31(10):1638-1640.

Urosevic-Maiwald, M; Mangana, J; Dummer, R (2017). Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma. Annals of Oncology, 28(7):1673-1675.

Thurneysen, S; Cheng, P F; Nagel, H W; Kunz, M; Jaberg-Bentele, N; Nägeli, M; Ziegler, M; Guenova, E; Goldinger, S M; Mangana, J; Levesque, M P; Dummer, R (2016). An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxel. British Journal of Dermatology, 175(5):966-978.

Matter-Walstra, Klazien; Braun, R; Kolb, C; Ademi, Z; Dummer, R; Pestalozzi, B C; Schwenkglenks, Matthias (2016). Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors. British Journal of Dermatology, 174(2):463.

Jenni, D; Karpova, M B; Mühleisen, B; Mangana, J; Dreier, J; Hafner, J; Dummer, R (2016). A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. ESMO Open, 1:e000003.

Kunz, M; Urosevic-Maiwald, M; Goldinger, S M; Frauchiger, A L; Dreier, J; Belloni, B; Mangana, J; Jenni, D; Dippel, M; Cozzio, A; Guenova, E; Kamarachev, J; French, L E; Dummer, R (2016). Efficacy and safety of oral alitretinoin in severe oral lichen planus - results of a prospective pilot study. Journal of the European Academy of Dermatology and Venerology, 30(2):293-298.

Guenova, E; Ignatova, D; Chang, Y; Contassot, E; Mehra, T; Saulite, I; Navarini, A; Mitev, V; Dummer, R; Kazakov, D V; French, L; Hötzenecker, W; Cozzio, A (2016). Expression of CD164 on malignant T Cells in Sézary syndrome. Acta Dermato-Venereologica, 96(4):464-467.

Urner-Bloch, U; Urner, M; Jaberg-Bentele, N; Frauchiger, A L; Dummer, R; Goldinger, S.M (2016). MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects. European Journal of Cancer, 65:130-138.

Frauchiger, A L; Mangana, J; Rechsteiner, M; Moch, H; Seifert, Burkhardt; Braun, R; Dummer, R; Goldinger, S M (2016). Prognostic relevance of LDH and serum S-100 levels in Stage IV melanoma with known BRAF mutation status. British Journal of Dermatology, 174(4):823-830.

Engeli, L; Moergeli, H; Binder, M; Drabe, N; Meier, C; Buechi, S; Dummer, R; Jenewein, J (2016). Resilience in patients and spouses faced with malignant melanoma. A qualitative longitudinal study. European Journal of Cancer Care, 25(1):122-131.

Dummer, R; Hauschild, A; Lindenblatt, N; Pentheroudakis, G; Keilholz, U (2015). Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 26 Suppl:v126-v132.

Lau, E; Sedy, J; Sander, C; Shaw, M A; Feng, Y; Scortegagna, M; Claps, G; Robinson, S; Cheng, P; Srivas, R; Soonthornvacharin, S; Ideker, T; Bosenberg, M; Gonzalez, R; Robinson, W; Chanda, S K; Ware, C; Dummer, R; Hoon, D; Kirkwood, J M; Ronai, Z A (2015). Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy. Oncogene, 34(46):5739-5748.

Matter-Walstra, K; Braun, R; Kolb, C; Ademi, Z; Dummer, R; Pestalozzi, B C; Schwenkglenks, M (2015). A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. British Journal of Dermatology, 173(6):1462-1470.

Mohr, P; Hauschild, A; Trefzer, U; Enk, A; Tilgen, W; Loquai, C; Gogas, H; Haalck, T; Koller, J; Dummer, R; Gutzmer, R; Brockmeyer, N; Holzle, E; Sunderkotter, C; Mauch, C; Stein, A; Schneider, L A; Podda, M; Goppner, D; Schadendorf, D; Weichenthal, M (2015). Intermittent high-dose intravenous interferon Alfa-2b for adjuvant treatment of stage III melanoma: Final analysis of a randomized phase III dermatologic cooperative oncology group trial. Journal of Clinical Oncology, 33(34):4077-4084.

Curioni-Fontecedro, A; Pitocco, R; Schoenewolf, N L; Holzmann, D; Soldini, D; Dummer, R; Calvieri, S; Moch, H; Mihic-Probst, D; Fitsche, A (2015). Intratumoral heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 expression in mucosal melanoma. BioMed Research International, 2015:432479.

Fujii, K; Karpova, M B; Asagoe, K; Georgiev, O; Dummer, R; Urosevic-Maiwald, M (2015). Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy. Leukemia, 29(10):2024-2032.

Dreier, J; Cheng, P F; Bogdan Alleman, I; Gugger, A; Hafner, J; Tschopp, A; Goldinger, S M; Levesque, M P; Dummer, R (2014). Basal cell carcinomas in a tertiary referral centre: a systematic analysis. British Journal of Dermatology, 171(5):1066-1072.

Guenova, E; Schanz, S; Hoetzenecker, W; DeSimone, J A; Mehra, T; Voykov, B; Urosevic-Maiwald, M; Berneburg, M; Dummer, R; French, L E; Kerl, K; Kamarashev, J; Fierlbeck, G; Cozzio, A (2014). Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma. British Journal of Dermatology, 171(4):891-894.

Dummer, R; Duvic, M; Scarisbrick, J; Olsen, E A; Rozati, S; Eggmann, N; Goldinger, S M; Hutchinson, K; Geskin, L; Illidge, T M; Giuliano, E; Elder, J; Kim, Y H (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Annals of Oncology, 25(9):1807-1812.

Urner-Bloch, U; Urner, M; Stieger, P; Galliker, N; Winterton, N; Zubel, A; Moutouh-de Parseval, L; Dummer, R; Goldinger, S M (2014). Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Annals of Oncology, 25(7):1437-1441.

Schadendorf, D; Amonkar, M M; Milhem, M; Grotzinger, K; Demidov, L V; Rutkowski, P; Garbe, C; Dummer, R; Hassel, J C; Wolter, P; Mohr, P; Trefzer, U; Lefeuvre-Plesse, C; Rutten, A; Steven, N; Ullenhag, G; Sherman, L; Wu, F S; Patel, K; Casey, M; Robert, C (2014). Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Annals of Oncology, 25(3):700-706.

Nägeli, M C; Dummer, R (2014). Vismodegib (Erivedge®). Swiss Medical Forum, 14(13):284-286.

Dummer, R; Mangana, J (2013). Carboplatin, paclitaxel and sorafenib in advanced melanoma – what have we learned? Translational Cancer Research, 2:46-47.

Bekou, V; Baltisser, I; Dummer, R; Traber, J (2013). Ulkus plantar bei multimorbidem Patienten. Der Chirurg, 84(3):222-224.

Dummer, R; Hauschild, A; Guggenheim, M; Keilholz, U; Pentheroudakis, G (2012). Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(Sup7):vii86-vii91.

Flaherty, K T; Robert, C; Hersey, P; Nathan, P; Garbe, C; Milhem, M; Demidov, L V; Hassel, J C; Rutkowski, P; Mohr, P; Dummer, R; Trefzer, U; Larkin, J; Utikal, J; Dreno, B; Casey, M; Sherman, L J; Wu, F S; Schadendorf, D (2012). Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group. New England Journal of Medicine, 367(2):107-114.

Hu, B; Castillo, E; Harewood, L; Ostano, P; Reymond, A; Dummer, R; Raffoul, W; Hoetzenecker, W; Hofbauer, G F; Dotto, G P (2012). Multifocal Epithelial Tumors and Field Cancerization from Loss of Mesenchymal CSL Signaling. Cell, 149(6):1207-1220.

Belloni, B; Johansen, N; Glass, L F; Dummer, R (2012). Recent advances in the management of cutaneous lymphomas. Seminars in Oncology, 39(2):150-162.

Barysch, M J; Eggmann, N; Beyeler, M; Panizzon, R; Seifert, Burkhardt; Dummer, R (2012). Long-term recurrence rate of large and difficult to treat cutaneous squamous cell carcinomas after superficial radiotherapy. Dermatology, 224(1):59-65.

Kerl, K; Kempf, W; Kamarachev, J; Spallone, G; Braun, R; Wiesner, T; French, L E; Dummer, R (2012). Constitutional Intraepidermal ascent of Melanocytes. A potential pitfall in the diagnosis of Melanocytic Lesions. Archives of Dermatology, 148(2):235-238.

Prinz Vavricka, B M; Hofbauer, G F L; Dummer, R; French, L E; Kempf, W (2012). Topical treatment of cutaneous Kaposi sarcoma with imiquimod 5% in renal-transplant recipients: a clinicopathological observation. Clinical and Experimental Dermatology, 37(6):620-625.

Dummer, R; Rinderknecht, J; Goldinger, S M (2012). Ultraviolet A and photosensitivity during vemurafenib therapy. New England Journal of Medicine, 366(5):480-481.

Dummer, R; Beyer, M; Hymes, K; Epping, M T; Bernards, R; Steinhoff, M; Sterry, W; Kerl, H; Heath, K; Ahern, J D; Hardwick, J S; Garcia-Vargas, J; Baumann, K; Rizvi, S; Frankel, S R; Whittacker, S J; Assaf, C (2012). Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leukemia and Lymphoma, 53(8):1501-1508.

Widmer, D S; Cheng, P F; Eichhoff, O M; Benedetta, C B; Zipser, M C; Schlegel, N C; Javelaud, D; Mauviel, A; Dummer, R; Hoek, K S (2012). Systematic classification of melanoma cells by phenotype-specific gene expression mapping. Pigment Cell & Melanoma Research, 25(3):343-353.

Eggermont, A M M; Suciu, S; Testori, A; Kruit, W H; Marsden, J; Punt, C J; Santinami, M; Salès, F; Schadendorf, D; Patel, P; Dummer, R; Robert, C; Keilholz, U; Yver, A; Spatz, A (2012). Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. European Journal of Cancer, 48(2):218-225.

Lin, W M; Lewis, J M; Filler, R B; Modi, B G; Carlson, K R; Reddy, S; Thornberg, A; Saksena, G; Umlauf, S; Oberholzer, P A; Karpova, M; Getz, G; Mane, S; Garraway, L A; Dummer, R; Berger, C L; Edelson, R L; Girardi, M (2012). Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. Journal of Investigative Dermatology, 132:188-197.

Dummer, R; Goldinger, S M; Cozzio, A; French, L E; Karpova, M B (2012). Cutaneous lymphomas: Molecular pathways leading to new drugs. Journal of Investigative Dermatology, 132(3):517-525.

Kempf, W; Rozati, S; Kerl, K; French, L E; Dummer, R (2012). Cutaneous peripheral T-cell lymphomas, unspecified/NOS and rare subtypes: a heterogeneous group of challenging cutaneous lymphomas. Giornale Italiano di Dermatologia e Venereologia, 147(6):553-562.

Whittaker, S; Ortiz, P; Dummer, R; Ranki, A; Hasan, B; Meulemans, B; Gellrich, S; Knobler, R; Stadler, R; Karrasch, M (2012). Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). British Journal of Dermatology, 167(3):678-687.

von Moos, R; Seifert, B; Simcock, M; Goldinger, S M; Gillessen, S; Ochsenbein, A; Michielin, O; Cathomas, R; Schläppi, M; Moch, H; Schraml, P H; Mihic-Probst, D; Mamot, C; Schönewolf, N; Dummer, R (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology, 23(2):531-536.

Dummer, R; Rozati, S; Eggmann, N; Rinderknecht, J; Goldinger, S M (2012). From chemotherapy to targeted treatment. Annals of Oncology, 23(Sup 10):x101-x103.

Dummer, R; Tsao, H; Robert, C (2012). How cutaneous eruptions help to understand the mode of action of kinase inhibitors. British Journal of Dermatology, 167(5):965-967.

Daud, A; Soon, C; Dummer, R; Eggermont, A M M; Hwu, W J; Grob, J J; Garbe, C; Hauschild, A (2012). Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opinion on Biological Therapy, 12(8):1087-1099.

Goldinger, S M; Romano, E; Michielin, O; Dummer, R (2012). Management und Beurteilung des Ansprechens von Ipilimumab bei Patienten mit Melanom. Swiss Medical Forum, 12(44):851-855.

Dummer, R; Goldinger, S; Rinderknecht, J; Eggmann, N; Felderer, L; Braun, R; French, L E (2012). Melanomtherapie - ein Paradigma für die «personalized medicine». Praxis, 101(15):955-959.

Kirkwood, J M; Bastholt, L; Robert, C; Sosman, J; Larkin, J; Hersey, P; Middleton, M; Cantarini, M; Zazulina, V; Kemsley, K; Dummer, R (2012). Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clinical Cancer Research, 18(2):555-567.

Schraml, P; von Teichman, A; Mihic-Probst, D; Simcock, M; Ochsenbein, A; Dummer, R; Michieilin, O; Seifert, B; Schläppi, M; Moch, H; von Moos, R (2012). Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology Reports, 28(2):654-658.

Schoenewolf, N L; Bull, C; Belloni, B; Holzmann, D; Tonolla, S; Lang, R; Mihic-Probst, D; Andres, C; Dummer, R (2012). Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. European Journal of Cancer, 48(12):1842-1852.

Mangana, J; Lévesque, M P; Karpova, M B; Dummer, R (2012). Sorafenib in melanoma. Expert Opinion on Investigational Drugs, 21(4):557-568.

Barysch, M J; Rümmelein, B; Kolm, I; Karpova, M B; Schönewolf, N; Bogdan Allemann, I; Dummer, R (2012). Split-face study of melasma patients treated with non-ablative fractionated photothermolysis (1540 nm). Journal of the European Academy of Dermatology and Venereology, 26(4):423-430.

Antsiferova, M; Huber, M; Meyer, Michael; Piwko-Czuchra, A; Ramadan, T; MacLeod, A S; Havran, W L; Dummer, R; Hohl, D; Werner, S (2011). Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response. Nature Communications, 2:576.

Kiowski, G; Biedermann, T; Widmer, D S; Civenni, G; Burger, C; Dummer, R; Sommer, L; Reichmann, E (2011). Engineering melanoma progression in a humanized environment in vivo. Journal of Investigative Dermatology, 132(1):144-153.

Zipser, M C; Eichhoff, O M; Widmer, D S; Schlegel, N C; Schoenewolf, N L; Stuart, D; Liu, W; Gardner, H; Smith, P D; Nuciforo, P; Dummer, R; Hoek, K S (2011). A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. Pigment Cell & Melanoma Research, 24(2):326-333.

Karpova, M B; Barysch, M J; Zipser, M C; Schönewolf, N; French, L E; Dummer, R (2011). Changing pathology with changing drugs: skin cancer. Pathobiology, 78(2):61-75.

Olsen, E A; Whittaker, S J; Kim, Y H; Duvic, M; Prince, H M; Lessin, S R; Wood, G S; Willemze, R; Demierre, M F; Pimpinelli, N; Bernengo, M G; Ortiz-Romero, P L; Bagot, M; Estrach, T; Guitart, J; Knobler, R; Sanches, J A; Iwatsuki, K; Sugaya, M; Dummer, R; Pittelkow, M; Hoppe, R; Parker, S; Geskin, L; Pinter-Brown, L; Girardi, M; Burg, G; Ranki, A; Vermeer, M H; Horwitz, S; Heald, P; Rosen, S; Cerroni, L; Dreno, B; Vonderheid, E C (2011). Clinical end points and response criteria in mycosis fungoides and sezary syndrome: a consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European organisation for research and treatment of cancer. Journal of Clinical Oncology, 29(18):2598-2607.

Dummer, R; Kawai, K; Zipser, M C (2011). Cutaneous lymphoma. In: Dummer, R; Pittelkow, M; Iwatsuki, K; Green, A; Elwan, N M. Skin cancer - a world-wide perspective. Heidelberg, DE: Springer, 343-354.

Burg, G; Kempf, W; Dummer, R; Urosevic-Maiwald, M (2011). Cutaneous lymphoma, leukemia and related disorders. In: Dummer, R; Pittelkow, M R; Iwatsuki, K; Green, A; Elwan, N M. Skin cancer - a world-wide perspective. Heidelberg, DE: Springer, 197-231.

Kolm, I; Dummer, R; Braun, R P (2011). Dermoscopy. In: Dummer, R; Pittelkow, M; Iwatsuki, K; Green, A; Elwan, N M. Skin cancer - a world-wide perspective. Heidelberg, DE: Springer, 373-378.

Guggenheim, M; Dummer, R; Giovanoli, P (2011). Die Rolle der Chirurgie in der Behandlung des kutanen Melanoms. Praxis, 100(15):911-916.

Frey, K; Fiechter, M; Schwager, K; Belloni, B; Barysch, M J; Neri, D; Dummer, R (2011). Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Experimental Dermatology, 20(8):685-688.

Eichhoff, O M; Weeraratna, A; Zipser, M C; Denat, L; Widmer, D S; Xu, M; Kriegl, L; Kirchner, T; Larue, L; Dummer, R; Hoek, K S (2011). Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell & Melanoma Research, 24(4):631-642.

Dummer, R; Kerl, K; Mihic, D; Kamarachev, J (2011). Differential diagnosis of melanocytic lesions and molecular biology. Archives of Dermatology, 147(2):232-233.

Kempf, W; Pfaltz, K; Vermeer, M H; Cozzio, A; Ortiz-Romero, P L; Bagot, M; Olsen, E; Kim, Y H; Dummer, R; Pimpinelli, N; Whittaker, S; Hodak, E; Cerroni, L; Berti, E; Horwitz, S; Prince, H M; Guitart, J; Estrach, T; Sanches, J A; Duvic, M; Ranki, A; Dreno, B; Ostheeren-Michaelis, S; Knobler, R; Wood, G; Willemze, R (2011). EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood, 118(15):218-225.

Urosevic-Maiwald, M (2011). Epidemiology of cutaneous lymphomas. In: Dummer, R; Pittelkow, M R; Iwatsuki, K; Green, A; Elwan, N M. Skin cancer - a world-wide perspective. Heidelberg, DE: Springer, 27-31.

Zipser, M C; Dummer, R (2011). Epidemiology of histocytoses. In: Dummer, R; Pittelkow, M R; Iwatsuki, K; Green, A; Elwan, N M. Skin cancer - a world-wide perspective. Heidelberg, DE: Springer, 33-34.

Karpova, M B; Fujii, K; Jenni, D; Dummer, R; Urosevic-Maiwald, M (2011). Evaluation of lymphangiogenic markers in Sézary syndrome. Leukemia and Lymphoma, 52(3):491-501.

Patel, P M; Suciu, S; Mortier, L; Kruit, W H; Robert, C; Schadendorf, D; Trefzer, U; Punt, C J A; Dummer, R; Davidson, N; Becker, Juergen; Conry, R; Thompson, J A; Hwu, W J; Engelen, K; Agarwala, S S; Keilholz, U; Eggermont, A M M; Spatz, A (2011). Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). European Journal of Cancer, 47(10):1476-1483.

Imhof, L; Kerl, K; Barysch, M J; Dummer, R; French, L E; Hofbauer, G F L (2011). Facial blaschkitis: case and review. Dermatology, 223(1):1-3.

Studer, G; Brown, M; Salgueiro, E B; Schmückle, H; Romancuk, N; Winkler, G; Lee, S J; Sträuli, A; Kissling, B; Dummer, R; Glanzmann, C (2011). Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent Cetuximab and IMRT. International Journal of Radiation Oncology, Biology and Physics, 81(1):110-117.

Kiessling, M K; Oberholzer, P A; Mondal, C; Karpova, M B; Zipser, M C; Lin, W M; Girardi, M; MacConaill, L E; Kehoe, S M; Hatton, C; French, L E; Garraway, L A; Polier, G; Süss, D; Klemke, C D; Krammer, P H; Gülow, K; Dummer, R (2011). High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood, 117(8):2433-2440.

Chapman, P B; Hauschild, A; Robert, C; Haanen, J B; Ascierto, P; Larkin, J; Dummer, R; Garbe, C; Testori, A; Maio, M; Hogg, D; Lorigan, P; Lebbe, C; Jouary, T; Schadendorf, D; Ribas, A; O'Day, S J; Sosman, J A; Kirkwood, J M; Eggermont, A M M; Dreno, B; Nolop, K; Li, J; Nelson, B; Hou, J; Lee, R J; Flaherty, K T; McArthur, A G (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 364(26):2507-2516.

Arozarena, I; Bischof, H; Gilby, D; Belloni, B; Dummer, R; Wellbrock, C (2011). In melanoma, beta-catenin is a suppressor of invasion. Oncogene, 30(45):4531-4543.

Schoenewolf, N L; Barysch, M J; Dummer, R (2011). Intense pulsed light. In: Allemann, B; Goldberg, D J. Basics in Dermatological Laser Applications. Basel, CH: Karger, 166-172.

Hatta, N; Elwan, N M; Weibel, L; Requena, L; Donghi, D; Hafner, J; Bode-Lesniewska, B; Asagoe, K (2011). Mastocytosis, vascular, muscular and fibrohistiocytic tumors. In: Dummer, R; Pittelkow, M; Iwatsuki, K; Green, A; Elwan, N M. Skin cancer - a world-wide perspective. Heidelberg, DE: Springer, 241-277.

Kamarashev, J A; Schärer, L; Zipser, M C; Lockwood, L L; Dummer, R; Krengel, S (2011). Melanocytic tumors. In: Dummer, R; Pittelkow, M; Iwatsuki, K; Green, A; Elwan, N M. Skin cancer - a world-wide perspective. Heidelberg, DE: Springer, 169-196.

Guggenheim, M; Giovanoli, P; Baumert, B G; Eigentler, T K; Garbe, C; Mangana, J; Dummer, R (2011). Melanoma. In: Dummer, R; Pittelkow, M; Iwatsuki, K; Green, A; Elwan, N M. Skin cancer - a world-wide perspective. Heidelberg, DE: Springer, 307-341.

Conzett, K B; Kolm, I; Jelcic, I; Kamarachev, J; Dummer, R; Braun, R P; French, L E; Linnebank, M; Hofbauer, G F (2011). Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report. Archives of Dermatology, 147(8):991-992.

Läuchli, S; Hafner, J; Hofbauer, G F L; Cozzio, A; Urosevic-Maiwald, M (2011). Non-melanoma skin cancer. In: Dummer, R; Pittelkow, M; Iwatsuki, K; Green, A; Elwan, N M. Skin cancer - a world-wide perspective. Heidelberg, DE: Springer, 289-305.

Kamarashev, J A; Kaddu, S (2011). Non-melanoma skin cancer: Appendageal tumours. In: Dummer, R; Pittelkow, M R; Iwatsuki, K; Green, A; Elwan, N M. Skin cancer - a world-wide perspective. Heidelberg, DE: Springer, 121-167.

Zipser, M C; Dummer, R (2011). Pathogenesis of histiocytoses. In: Dummer, R; Pittelkow, M; Iwatsuki, K; Green, A; Elwan, N M. Skin cancer - a world-wide perspective. Heidelberg, DE: Springer, 73-74.

Sánchez-Schmidt, J M; Salgado, R; Servitje, O; Gallardo, F; Ortiz-Romero, P L; Karpova, M B; Zipser, M C; García-Muret, M P; Estrach, T; Rodríguez-Pinilla, S M; Climent, F; Suela, J; Ferreira, B I; Cigudosa, J C; Salido, M; Barranco, C; Serrano, S; Dummer, R; Solé, F; Pujol, R M; Espinet, B (2011). Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide arrayCGH approach. Journal of Investigative Dermatology, 131(1):269-271.

Jenni, D; Karpova, M B; Seifert, Burkhardt; Golling, P; Cozzio, A; Kempf, W; French, L E; Dummer, R (2011). Primary cutaneous lymphoma: Two-decade comparison in a population of 263 cases from a Swiss tertiary referral centre. British Journal of Dermatology, 164(5):1071-1077.

Navarini, A A; Bauer, J; Barysch, M J; Kempf, W; Mihic-Probst, D; Kerl, K; Kamarashev, J; Giovanoli, P; Kolios, A G A; Bergstraesser, E; Dummer, R (2011). Spitzoid melanoma and micrometastases in two lymph node regions: a critical situation. European Journal of Dermatology, 21(2):229-233.

Imhof, L; Goldinger, S M; Baumann, K; Schad, K; French, L E; Röthlisberger, P; Dummer, R (2011). The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. Melanoma Research, 21(1):80-83.

Schoenewolf, N L; Urosevic-Maiwald, M; Dummer, R (2011). Tumour heterogeneity of mucosal melanomas during treatment with imatinib. British Journal of Dermatology, 165(2):419-424.

Dummer, R; Guggenheim, M; Arnold, A W; Braun, R; von Moos, R (2011). Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Medical Weekly, 141:w13320.

Speiser, D E; Schwarz, K; Baumgaertner, P; Conzett, K B; Manolova, V; Devevre, E; Sterry, W; Walden, P; Zippelius, A; Senti, G; Voelter, V; Cerottini, J P; Guggisberg, D; Willers, J; Geldhof, C; Romero, P; Kündig, T; Knuth, A; Dummer, R; Trefzer, U; Bachmann, M F (2010). Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Journal of Immunotherapy, 33(8):848-858.

Lee, S B; Schramme, A; Doberstein, K; Dummer, R; Abdel-Bakky, M S; Keller, S; Altevogt, P; Oh, S T; Reichrath, J; Oxmann, D; Pfeilschifter, J; Mihic-Probst, D; Gutwein, P (2010). ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. Journal of Investigative Dermatology, 130(3):763-773.

Ungerer, C; Doberstein, K; Bürger, C; Hardt, K; Boehncke, W H; Böhm, B; Pfeilschifter, J; Dummer, R; Mihic-Probst, D; Gutwein, P (2010). ADAM15 expression is downregulated in melanoma metastasis compared to primary melanoma. Biochemical and Biophysical Research Communications (BBRC), 401(3):363-369.

Dummer, R; Goldinger, S M; Sailer, E; French, L E (2010). Aktuelle Therapie des Melanoms der Haut. Therapeutische Umschau, 67(9):447-452.

Fontecedro, A C; Lutschg, V; Eichhoff, O; Dummer, R; Greber, U F; Hemmi, S (2010). Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro. Virology Journal, 7(1):175.

Johannessen, C M; Boehm, J S; Kim, S Y; Thomas, S R; Wardwell, L; Johnson, L A; Emery, C M; Stransky, N; Cogdill, A P; Barretina, J; Caponigro, G; Hieronymus, H; Murray, R R; Salehi-Ashtiani, K; Hill, D E; Vidal, M; Zhao, J J; Yang, X; Alkan, O; Kim, S; Harris, J L; Wilson, C J; Myer, V E; Finan, P M; Root, D E; Roberts, T M; Golub, T; Flaherty, K T; Dummer, R; Weber, B L; Sellers, W R; Schlegel, R; Wargo, J A; Hahn, W C; Garraway, L A (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468(7326):968-972.

Donghi, D; Dummer, R; Cozzio, A (2010). Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib. British Journal of Dermatology, 162(3):697-699.

Donghi, D; Kerl, K; Dummer, R; Schoenewolf, N; Cozzio, A (2010). Cutaneous angiosarcoma: own experience over 13 years. Clinical features, disease course and immunohistochemical profile. Journal of the European Academy of Dermatology and Venereology, 24(10):1230-1234.

Berger, M F; Levin, J Z; Vijayendran, K; Sivachenko, A; Adiconis, X; Maguire, J; Johnson, L A; Robinson, J; Verhaak, R G; Sougnez, C; Onofrio, R C; Ziaugra, L; Cibulskis, K; Laine, E; Barretina, J; Winckler, W; Fisher, D E; Getz, G; Meyerson, M; Jaffe, D B; Gabriel, S B; Lander, E S; Dummer, R; Gnirke, A; Nusbaum, C; Garraway, L A (2010). Integrative analysis of the melanoma transcriptome. Genome Research, 20(4):413-427.

Barysch, M J; Cozzio, A; Kolm, I; Hrdlicka, S R; Brand, C; Hunger, R; Kreyden, O; Schaffner, R; Zaugg, T; Dummer, R (2010). Internet based health promotion campaign against skin cancer - Results of www.skincheck.ch in Switzerland. European Journal of Dermatology, 20(1):109-114.

Hassel, J C; Sucker, A; Edler, L; Kurzen, H; Moll, I; Stresemann, C; Spieth, K; Mauch, C; Rass, K; Dummer, R; Schadendorf, D (2010). MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. British Journal of Cancer, 103(6):820-826.

Zipser, M C; Mangana, J; Oberholzer, P A; French, L E; Dummer, R (2010). Melanoma after laser therapy of pigmented lesions - circumstances and outcome. European Journal of Dermatology, 20(3):334-338.

Dummer, R; Hauschild, A; Guggenheim, M; Jost, L; Pentheroudakis, G (2010). Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21(Sup. 5):v194-v197.

Schad, K; Baumann Conzett, K; Zipser, M C; Enderlin, V; Kamarashev, J; French, L E; Dummer, R (2010). Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clinical Cancer Research, 16(3):1058-1064.

Dummer, R; Eichmüller, S; Gellrich, S; Assaf, C; Dreno, B; Schiller, M; Dereure, O; Baudard, M; Bagot, M; Khammari, A; Bleuzen, P; Bataille, V; Derbij, A; Wiedemann, N; Waterboer, T; Lusky, M; Acres, B; Urosevic-Maiwald, M (2010). Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Molecular Therapy, 18(6):1244-1247.

Mangana, J; Dziunycz, P; Kerl, K; Dummer, R; Cozzio, A (2010). Prevalence of Merkel cell polyomavirus among Swiss Merkel cell carcinoma patients. Dermatology, 221(2):184-188.

Eichhoff, O M; Zipser, M C; Xu, M; Weeraratna, A T; Mihic, D; Dummer, R; Hoek, K S (2010). The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report. Melanoma Research, 20(4):349-355.

Barysch, M J; Hofbauer, G F L; Dummer, R (2010). Vitamin D, ultraviolet exposure, and skin cancer in the elderly. Gerontology, 56(4):410-413.

Barysch, M J; Feldmeyer, L; Bischoff-Ferrari, H; Hofbauer, G; Dummer, R (2010). Vitamine D, ultraviolets et cancer de la peau. Revue Médicale Suisse, 6(246):884-885.

Dummer, R; Gobbi, S H; Rinderknecht, J; Goldinger, S M (2010). Zielgerichtete Therapie bei Hautmalignomen. Endlich messbare Erfolge! Swiss Medical Forum, 10(51-52):901-903.

Salgado, R; Servitje, O; Gallardo, F; Vermeer, M H; Ortiz-Romero, P L; Karpova, M B; Zipser, M C; Muniesa, C; García-Muret, M P; Estrach, T; Salido, M; Sánchez-Schmidt, J; Herrera, M; Romagosa, V; Suela, J; Ferreira, B I; Cigudosa, J C; Barranco, C; Serrano, S; Dummer, R; Tensen, C P; Solé, F; Pujol, R M; Espinet, B (2009). Oligonucleotide array-cgh identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. Journal of Investigative Dermatology, 130(4):1126-1135.

Mandinova, A; Kolev, V; Neel, V; Hu, B; Stonely, W; Lieb, J; Wu, X; Colli, C; Han, R; Pazin, M; Ostano, P; Dummer, R; Brissette, J L; Dotto, G P (2009). A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. Journal of Clinical Investigation, 119(10):3127-3137.

Dummer, R; Karpova, M; Barysch, M J (2009). Basal cell carcinomas: molecular abnormalities and molecularly targeted therapies. Expert Review of Dermatology, 4(4):355-369.

Schlegel, N C; Eichhoff, O M; Hemmi, S; Werner, S; Dummer, R; Hoek, K S (2009). Id2 suppression of p15 counters TGF-beta-mediated growth inhibition of melanoma cells.counters TGF-beta-mediated growth inhibition of melanoma cells. Pigment Cell & Melanoma Research, 22(4):445-453.

Barysch, M J; Bischoff-Ferrari, H A; Hofbauer, G; Dummer, R (2009). Vitamin D, UV-Strahlung und Hautkrebs. Schweizerische Ärztezeitung, 90(36):1372-1373.

Braun, R P; Kolm, I; Dummer, R; Hafner, J; French, L (2009). Diagnostik des malignen Melanoms: Hautkrebsvorsorge-Sprechstunde der Dermatologischen Klinik des Universitätsspitals Zürich. Medicos, 10(1):6-11.

Bazhin, A V; Dalke, C; Willner, N; Abschütz, O; Wildberger, H G H; Philippov, P P; Dummer, R; Graw, J; Hrabé de Angelis, M; Schadendorf, D; Umansky, V; Eichmüller, S B (2009). Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy. International Journal of Cancer, 124(1):140-149.

Mnich, C D; Hoek, K S; Virkki, L V; Farkas, A; Dudli, C; Laine, E; Urosevic, M; Dummer, R (2009). Green tea extract reduces induction of p53 and apoptosis in UVB-irradiated human skin independent of transcriptional controls. Experimental Dermatology, 18(1):69-77.

Bottomley, A; Coens, C; Suciu, S; Santinami, M; Kruit, W; Testori, A; Marsden, J; Punt, C; Salès, F; Gore, M; Mackie, R; Kusic, Z; Dummer, R; Patel, P; Schadendorf, D; Spatz, A; Keilholz, U; Eggermont, A (2009). Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. Journal of Clinical Oncology, 27(18):2916-2923.

Gogas, H; Eggermont, A M M; Hauschild, A; Hersey, P; Mohr, P; Schadendorf, D; Spatz, A; Dummer, R (2009). Biomarkers in melanoma. Annals of Oncology, 20(Suppl):vi8-vi13.

Dummer, R; Hauschild, A; Pentheroudakis, G (2009). Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 20(Suppl 4):iv129-iv131.

Dummer, R (2009). Epitheliale Neoplasien der Haut. Epidemiologie, klinisches Spektrum, heutige Therapieoptionen. Schweizer Zeitschrift für Onkologie, (2):6-10.

Oberholzer, P A; Cozzio, A; Dummer, R; French, L E; Hofbauer, G F L (2009). Granulomatous slack skin responds to UVA1 phototherapy. Dermatology, 219(3):268-271.

Dummer, R (2009). Hautmalignome: Immer häufiger, teurer – aber meist heilbar. Schweizer Zeitschrift für Onkologie, (2):1.

Ballmer Conzett, K; Schad, K; Cozzio, A; French, L E; Dummer, R (2009). Kutane Lymphome. Stadieneinteilung und Therapieempfehlungen. Swiss Medical Forum, (42):744-749.

Lübbe, J; Anliker, M; Bernier, J; Borner, M; Dummer, R; Helbling, D; Hohl, D; Hunziker, T; Itin, P; Köberle, D; Pestalozzi, B; Rauch, D; Surber, C (2009). Kutane Nebenwirkungen der Therapie mit EGFR-Inhibitoren Klinische Einteilung und Behandlung. Dermatologica Helvetica, (5):19-23.

Strobel, K; Bode, B; Dummer, R; Veit-Haibach, P; Fischer, D R; Imhof, L; Goldinger, S; Steinert, H C; von Schulthess, G K (2009). Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 36(11):1774-1782.

Dummer, R; Mangana, J (2009). Long-term pegylated interferon-alpha and its potential in the treatment of melanoma. Biologics: Targets & Therapy, 3:169-182.

Emery, C M; Vijayendran, K G; Zipser, M C; Sawyer, A M; Niu, L; Kim, J J; Hatton, C; Chopra, R; Oberholzer, P A; Karpova, M B; MacConaill, L E; Zhang, J; Gray, N S; Sellers, W R; Dummer, R; Garraway, L A (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 106(48):20411-20416.

Cathomas, R; Zbinden, S; Dummer, R; Gillessen, S; Margulies, A; Torresan, E; Stenner-Liewen, F (2009). Management der unerwünschten Wirkungen unter Sunitinib. Empfehlungen für die Therapie beim metastasierten Nierenzellkarzinom. Schweizer Zeitschrift für Onkologie, (3):24-27.

Farkas, A; Kemeny, L; French, L E; Dummer, R (2009). New and experimental skin-directed therapies for cutaneous lymphomas. Skin Pharmacology and Physiology, 22(6):322-334.

Hersey, P; Bastholt, L; Chiarion-Sileni, V; Cinat, G; Dummer, R; Eggermont, A M M; Espinosa, E; Hauschild, A; Quirt, I; Robert, C; Schadendorf, D (2009). Small molecules and targeted therapies in distant metastatic disease. Annals of Oncology, 20(Suppl):vi35-vi40.

Hoek, K S; Eichhoff, O M; Widmer, D; Dummer, R (2009). Stemming the flood. Pigment Cell & Melanoma Research, 22(1):6-7.

Kamarashev, J; French, L E; Dummer, R; Kerl, K (2009). Symplastic glomus tumor - a rare but distinct benign histological variant with analogy to other 'ancient' benign skin neoplasms. Journal of Cutaneous Pathology, 36(10):1099-1102.

Barysch, M J; Dummer, R (2009). The spectrum of widespread hyperpigmentations from SLN to SUL. Archives of Dermatology, 145(8):953-954.

Dummer, R (2009). Was hilft gegen Narben? Gesundheit Sprechstunde, 7/2009:28-29.

Dummer, R (2009). Wenn die Haut Störsignale sendet. Hausarzt Praxis, (12):7.

Hoek, K S; Schlegel, N C; Eichhoff, O M; Widmer, D S; Praetorius, C; Einarsson, S O; Valgeirsdottir, S; Bergsteinsdottir, K; Schepsky, A; Dummer, R; Steingrimsson, E (2008). Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell & Melanoma Research, 21(6):665-676.

Szeimies, R M; Ibbotson, S; Murrell, D F; Rubel, D; Frambach, Y; de Berker, D; Dummer, R; Kerrouche, N; Villemagne, H (2008). A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology, 22(11):1302-1311.

Strobel, K; Dummer, R; Steinert, H C; Baumann Conzett, K; Schad, K; Pérez Lago, M; Soyka, J D; Veit-Haibach, P; Seifert, Burkhardt; Kalff, V (2008). Chemotherapy response assessment in stage IV melanoma patients-comparison of (18)F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. European Journal of Nuclear Medicine and Molecular Imaging, 35(10):1786-1795.

Oberholzer, P A; Urosevic, M; Steinert, H C; Dummer, R (2008). Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography. Dermatology, 217(4):351-355.

Hauschild, A; Dummer, R; Ugurel, S; Kaehler, K C; Egberts, F; Fink, W; Both-Skalsky, J; Laetsch, B; Schadendorf, D (2008). Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study. Cancer, 113(6):1404-1411.

Mangana, J; Zipser, M C; Conrad, C; Oberholzer, P A; Cozzio, A; Knuth, A; French, L E; Dummer, R (2008). Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. European Journal of Dermatology, 18(5):566-570.

Tun-Kyi, A; Qin, J Z; Oberholzer, P A; Navarini, A A; Hassel, J C; Dummer, R; Döbbeling, U (2008). Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model. Annals of Oncology, 19(8):1488-1494.

Kolev, V; Mandinova, A; Guinea-Viniegra, J; Hu, B; Lefort, K; Lambertini, C; Neel, V; Dummer, R; Wagner, E F; Dotto, G P (2008). EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nature Cell Biology, 10(8):902-911.

Garbe, C; Radny, P; Linse, R; Dummer, R; Gutzmer, R; Ulrich, J; Stadler, R; Weichenthal, M; Eigentler, T K; Ellwanger, U; Hauschild, A (2008). Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Annals of Oncology, 19(6):1195-1201.

Golling, P; Cozzio, A; Dummer, R; French, L; Kempf, W (2008). Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome. Leukemia and Lymphoma, 49(6):1094-1103.

Dummer, R; Hauschild, A; Jost, L (2008). Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 19(Suppl):ii86-ii88.

Dummer, R; Schadendorf, D (2008). How melanoma is treated in real life. Archives of Dermatology, 144(5):664-665.

Dummer, R; Rochlitz, C; Velu, T; Acres, B; Limacher, J M; Bleuzen, P; Lacoste, G; Slos, P; Romero, P; Urosevic, M (2008). Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Molecular Therapy, 16(5):985-994.

Dummer, R; Dreyling, M (2008). Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 19(Suppl):ii72-ii76.

Stadler, R; Assaf, C; Klemke, C D; Nashan, D; Weichenthal, M; Dummer, R; Sterry, W (2008). Short German guidelines: cutaneous lymphomas. Journal der Deutschen Dermatologischen Gesellschaft, 6(Suppl):S25-S31.

Garbe, C; Schadendorf, D; Stolz, W; Volkenandt, M; Reinhold, U; Kortmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R; Hauschild, A (2008). Short German guidelines: malignant melanoma. Journal der Deutschen Dermatologischen Gesellschaft, 6(Suppl):S9-S14.

Hofbauer, G F L; Baur, T; Bonnet, M C; Tartour, E; Burg, G; Berinstein, N L; Dummer, R (2008). Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Research, 18(2):104-111.

Garbe, C; Hauschild, A; Volkenandt, M; Schadendorf, D; Stolz, W; Reinhold, U; Kortmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R (2008). Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Research, 18(2):152-160.

von Moos, R; Thuerlimann, B J K; Aapro, M; Rayson, D; Harrold, K; Sehouli, J; Scotte, F; Lorusso, D; Dummer, R; Lacouture, M E; Lademann, J; Hauschild, A (2008). Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. European Journal of Cancer, 44(6):781-790.

Spieth, K; Kaufmann, R; Dummer, R; Garbe, C; Becker, J C; Hauschild, A; Tilgen, W; Ugurel, S; Beyeler, M; Bröcker, E B; Kaehler, K C; Pföhler, C; Gille, J; Leiter, U; Schadendorf, D (2008). Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the dermatologic cooperative oncology group (DeCOG). Annals of Oncology, 19(4):801-806.

Dummer, R; Hauschild, A; Becker, J C; Grob, J J; Schadendorf, D; Tebbs, V; Skalsky, J; Kaehler, K C; Moosbauer, S; Clark, R; Meng, T C; Urosevic, M (2008). An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clinical Cancer Research, 14(3):856-864.

Garbe, C; Hauschild, A; Volkenandt, M; Schadendorf, D; Stolz, W; Reinhold, U; Kortmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R (2008). Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Research, 18(1):61-67.

Urosevic, M; Dummer, R (2008). Human leukocyte antigen-G and cancer immunoediting. Cancer Research, 68(3):627-630.

Hoek, K S; Eichhoff, O M; Schlegel, N C; Döbbeling, U; Kobert, N; Schaerer, L; Hemmi, S; Dummer, R (2008). In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Research, 68(3):650-656.

Lin, W M; Baker, A C; Beroukhim, R; Winckler, W; Feng, W; Marmion, J M; Laine, E; Greulich, H; Tseng, H; Gates, C; Hodi, F S; Dranoff, G; Sellers, W R; Thomas, R K; Meyerson, M; Golub, T R; Dummer, R; Herlyn, M; Getz, G; Garraway, L A (2008). Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Research, 68(3):664-673.

Bernier, J; Bonner, J; Vermorken, J B; Bensadoun, R J; Dummer, R; Giralt, J; Kornek, G; Hartley, A; Mesia, R; Robert, C; Segaert, S; Ang, K K (2008). Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Annals of Oncology, 19(1):142-149.

Beyeler, M; Hoek, K; Dummer, R (2008). Voodoo medicine still going strong: a tale of melanoma, faith, and failure. Archives of Dermatology, 144(1):121-122.

Eggermont, A M M; Suciu, S; Santinami, M; Testori, A; Kruit, W H J; Marsden, J; Punt, C J A; Salès, F; Gore, M; Mackie, R; Kusic, Z; Dummer, R; Hauschild, A; Musat, E; Spatz, A; Keilholz, U (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet, 372(9633):117-126.

Dummer, R; Hofer, T (2008). Der Nationale Hautkrebstag vom 07. Mai 2007: Eine kritische Auswertung. Dermatologica Helvetica, (2):8-10.

Kempf, W; Ostheeren-Michaelis, S; Paulli, M; Lucioni, M; Wechsler, J; Audring, H; Assaf, C; Rüdiger, T; Willemze, R; Meijer, C J L M; Berti, E; Cerroni, L; Santucci, M; Hallermann, C; Berneburg, M; Chimenti, S; Robson, A; Marschalko, M; Kazakov, D V; Petrella, T; Fraitag, S; Carlotti, A; Courville, P; Laeng, H; Knobler, R; Golling, P; Dummer, R; Burg, G (2008). Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Archives of Dermatology, 144(12):1609-1617.

Reschke, M; Mihic-Probst, D; van der Horst, E H; Knyazev, P; Wild, P J; Hutterer, M; Meyer, S; Dummer, R; Moch, H; Ullrich, A (2008). HER3 is a determinant for poor prognosis in melanoma. Clinical Cancer Research, 14(16):5188-5197.

Dummer, R (2008). Pigmentnävi und maligne Hauttumoren: Erstrangige Problematik – leidiger Podestplatz für die Schweiz. Hausarzt Praxis, (19):7.

Guggenheim, M; Dummer, R; Jung, F J; Mihic-Probst, D; Steinert, H; Rousson, V; French, L E; Giovanoli, P (2008). The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma - a retrospective analysis of 392 cases. British Journal of Cancer, 98(12):1922-1928.

Dummer, R; Hofer, T (2008). Vielen Dank für Ihr Engagement am nationalen Hautkrebstag, 05. Mai 2008! Hier ein kurzer Bericht. Dermatologica Helvetica, (10):12-15.

Enderlin, V; Dummer, R (2008). Vielfalt der malignen Hauttumoren: Früherkennung, differenzierte Therapie und Nachsorge. Hausarzt Praxis, (19):15-19.

Strobel, K; Skalsky, J; Kalff, V; Baumann, K; Seifert, Burkhardt; Joller-Jemelka, H; Dummer, R; Steinert, H C (2007). Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. European Journal of Nuclear Medicine and Molecular Imaging, 34(9):1366-1375.

Goldinger, S M; Dummer, R; Schmid, P; Burg, G; Seifert, Burkhardt; Läuchli, S (2007). Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. Journal of the European Academy of Dermatology and Venereology, 21(4):504-508.

Mihic-Probst, D; Kuster, A; Kilgus, S; Bode-Lesniewska, B; Ingold-Heppner, B; Leung, C; Storz, M; Seifert, Burkhardt; Marino, S; Schraml, P; Dummer, R; Moch, H (2007). Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. International Journal of Cancer, 121(8):1764-1770.

Mnich, C D; Hoek, K S; Oberholzer, P A; Seifert, Burkhardt; Hafner, J; Dummer, R; Mihic, D (2007). Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness. Melanoma Research, 17(2):131-136.

Strobel, K; Skalsky, J; Steinert, H C; Dummer, R; Hany, T F; Bhure, U; Seifert, Burkhardt; Pérez Lago, M; Joller-Jemelka, H; Kalff, V (2007). S-100B and FDG-PET/CT in therapy response assessment of melanoma patients. Dermatology, 215(3):192-201.

Schmitz, M; Graf, C; Gut, T; Sirena, D; Peter, I; Dummer, R; Greber, U F; Hemmi, S (2006). Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa- and fiber-modified replication-competent adenoviruses. Gene Therapy, 13(11):893-905.

Mihic-Probst, D; Mnich, C D; Oberholzer, P A; Seifert, Burkhardt; Sasse, B; Moch, H; Dummer, R (2006). p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. International Journal of Cancer, 118(9):2262-2268.

Hafner, J; Schmid, M H; Kempf, W; Burg, G; Künzi, W; Meuli-Simmen, C; Neff, P; Meyer, V; Mihic, D; Garzoli, E; Jungius, K P; Seifert, Burkhardt; Dummer, R; Steinert, H (2004). Baseline staging in cutaneous malignant melanoma. British Journal of Dermatology, 150(4):677-686.

Meier, S; Baumert, B G; Maier, T; Wellis, G; Burg, G; Seifert, Burkhardt; Dummer, R (2004). Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie, 27(2):145-149.

Peter, I; Graf, C; Dummer, R; Schaffner, W; Greber, U F; Hemmi, S (2003). A novel attenuated replication-competent adenovirus for melanoma therapy. Gene Therapy, 10(7):530-9.

Zagrodnik, B; Kempf, W; Seifert, Burkhardt; Müller, B; Burg, G; Urosevic, M; Dummer, R (2003). Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer, 98(12):2708-2714.

Hofbauer, G F L; Böni, R; Simmen, D; Mihic, D; Nestle, F O; Burg, G; Dummer, R (2002). Histological, immunological and molecular features of a nasal mucosa primary melanoma associated with nasal melanosis. Melanoma research, 12(1):77-82.

Schnorf, M; Helfenstein, Ulrich; Blum, A; Ellwanger, U; Garbe, C; Burg, G; Dummer, R (2001). Erhebungen zur "prätherapeutischen Phase" des malignen Melanoms der Haut in der Schweiz in den Jahren 1996-1998. Praxis, 90(50):2193-2198.

Laetsch, B; Häffner, A C; Döbbeling, U; Seifert, Burkhardt; Ludwig, E; Burg, G; Dummer, R (2000). CD4 + /CD7- T cell frequency and polymerase chain reaction-based clonality assay correlate with stage in cutaneous T cell lymphomas. Journal of Investigative Dermatology, 114(1):107-111.

Wimmer, I; Meyer, J C; Seifert, Burkhardt; Dummer, R; Flace, A; Burg, G (1997). Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Research, 57(22):5073-5076.

Rajan, G P; Seifert, Burkhardt; Prümmer, O; Joller-Jemelka, H I; Burg, G; Dummer, R (1996). Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA. Archives of Dermatological Research, 288(9):543-8.

Dummer, R; Welters, H; Keilholz, U; Tilgen, W; Burg, G (1990). Interleukin 2: immunologic background and clinical use in tumor therapy. Der Hautarzt, 41(2):53-55.

This list was generated on Thu Jun 27 03:33:12 2019 CEST.